A previous study was able to demonstrate that disruption of the transport metabolon with an antibody, targeted against the CAIX-binding site in CD147, reduces proton-coupled lactate transport and inhibits proliferation of breast cancer cells under hypoxia [12]. Here, CA9 is linked to breast cancer.